Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to -$4.7 million.

  • Tarsus Pharmaceuticals' Cash from Investing Activities fell 251.63% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.0 million, marking a year-over-year decrease of 23.97%. This contributed to the annual value of -$199.2 million for FY2024, which is 241.67% down from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Cash from Investing Activities is -$4.7 million, which was up 90.83% from -$51.7 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $64.1 million during Q2 2023, with a 5-year trough of -$102.2 million in Q1 2024.
  • Its 3-year average for Cash from Investing Activities is -$13.6 million, with a median of -$4.7 million in 2025.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Cash from Investing Activities tumbled by 47,112.40% in 2022 and then skyrocketed by 52,634.43% in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$274,000 in 2021, then crashed by 31,731.75% to -$87.2 million in 2022, then spiked by 120.47% to $17.9 million in 2023, then tumbled by 433.75% to -$59.6 million in 2024, then plummeted by 251.63% to -$4.7 million in 2025.
  • Its Cash from Investing Activities stands at -$4.7 million for Q3 2025, versus -$51.7 million for Q2 2025 and -$34.9 million for Q1 2025.